Decursin | 前胡素 | (+)-Decursin | Anti-tumor Agent | AmBeed-信号通路专用抑制剂

Decursin/紫花前胡素 {[allProObj[0].p_purity_real_show]}

货号：A909799 同义名： 前胡素 / (+)-Decursin

Decursin ((+)-Decursin) 是一种有效的抗癌剂，具有细胞毒性和强效激活蛋白激酶 C (PKC) 的作用。Decursin 诱导细胞凋亡和 G1 期细胞周期停滞。Decursin 在 48 小时内减少 CDK2、CDK4、CDK6 和 cyclin D1 蛋白的表达。Decursin 抑制细胞增殖和迁移，具有抗肿瘤、抗炎和镇痛活性。

Decursin/紫花前胡素化学结构
CAS号：5928-25-6

Decursin/紫花前胡素 3D分子结构
CAS号：5928-25-6

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

VEGFR 亚型比较

CXCR 亚型比较

PKC 亚型比较

转化生长因子-β 亚型比较

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2, IC50: 3 nM VEGFR2/Flk1, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	RET,PDGFR	97%
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ Flk1, IC50: 25 nM VEGFR2, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	c-Kit,PDGFR,FGFR	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/Flk1, IC50: 270 nM VEGFR2/KDR, IC50: 37 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Kit,c-Fms/CSF1R	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/Flk1, IC50: 0.18 nM VEGFR2/KDR, IC50: 0.2 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	c-Kit,BTK	98%
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ hVEGFR2, IC50: 9 nM mVEGF2, IC50: 165 nM	+ hVEGFR3, IC50: 420 nM		99%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			99%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	99%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Apatinib mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	99%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2, IC50: 90 nM VEGFR2/Flk1, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			98%
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	99%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	RET,FLT3	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	CXCR1 ↓ ↑	CXCR2 ↓ ↑	CXCR4 ↓ ↑	纯度
Reparixin	✔			99%+
SB225002		+++ CXCR2, IC50: 22 nM		99%+
Plerixafor			++ CXCR4, IC50: 44 nM	99%
AMD 3465 6HBr			✔	98%
WZ811			++++ CXCR4, EC50: 0.3 nM	99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	PKC ↓ ↑	PKCα ↓ ↑	PKCβ ↓ ↑	PKCγ ↓ ↑	PKCδ ↓ ↑	PKCε ↓ ↑	PKCζ ↓ ↑	PKCη ↓ ↑	PKCθ ↓ ↑	其他靶点	纯度
Daphnetin	+ PKC, IC50: 25.01 μM									EGFR,PKA	95%
Dequalinium Chloride											99%+
Quercetin	✔									Sirtuin,Src	95%
Myricetrin		✔									96%
Go 6983		+++ PKCα, IC50: 7 nM	+++ PKCβ, IC50: 7 nM	+++ PKCγ, IC50: 6 nM	+++ PKCδ, IC50: 10 nM		++ PKCζ, IC50: 60 nM				99%+
Go6976	+++ PKC, IC50: 7.9 nM	++++ PKCα, IC50: 2.3 nM	+++ PKCβ1, IC50: 6.2 nM							FLT3	99%+
Bisindolylmaleimide I		+++ PKCα, IC50: 20 nM	+++ PKCβ2, IC50: 16 nM PKCβ1, IC50: 17 nM	+++ PKCγ, IC50: 20 nM							99%+
Lawsone methyl ether			✔								99%
Sotrastaurin		++++ PKCα, Ki: 0.95 nM	++++ PKCβ1, Ki: 0.64 nM		++++ PKCδ, Ki: 2.1 nM	++++ PKCε, Ki: 3.2 nM		++++ PKCη, Ki: 1.8 nM	++++ PKCθ, Ki: 0.22 nM		99%+
Enzastaurin		++ PKCα, IC50: 39 nM	+++ PKCβ, IC50: 6 nM	+ PKCγ, IC50: 83 nM		+ PKCε, IC50: 110 nM					98%
Midostaurin		++ PKCα, IC50: 22 nM	++ PKCβ2, IC50: 31 nM PKCβ1, IC50: 30 nM	++ PKCγ, IC50: 24 nM	+ PKCδ, IC50: 330 nM	+ PKCε, IC50: 1.25 μM		+ PKCη, IC50: 160 nM			99%
Ro 31-8220 mesylate		++++ PKCα, IC50: 5 nM	+++ PKCβ2, IC50: 14 nM PKCβ1, IC50: 24 nM	++ PKCγ, IC50: 27 nM		++ PKCε, IC50: 24 nM					99%+
Staurosporine		++++ PKCα, IC50: 2 nM		++++ PKCγ, IC50: 5 nM	+++ PKCδ, IC50: 20 nM	++ PKCε, IC50: 73 nM		++++ PKCη, IC50: 4 nM			99%+
Ruboxistaurin HCl		+ PKCα, IC50: 0.36 μM	++++ PKCβ2, IC50: 5.9 nM PKCβ1, IC50: 4.7 nM	+ PKCγ, IC50: 0.3 μM	+ PKCδ, IC50: 0.25 μM			++ PKCη, IC50: 0.052 μM			99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	ALK1 ↓ ↑	ALK2 ↓ ↑	ALK3 ↓ ↑	ALK4 ↓ ↑	ALK6 ↓ ↑	Smad3 ↓ ↑	TGF-β ↓ ↑	TGFβRI/ALK5 ↓ ↑	TGFβRII ↓ ↑	纯度
LDN193189	++++ ALK1, IC50: 0.8 nM	++++ ALK2, IC50: 0.8 nM	+++ ALK3, IC50: 5.3 nM		+++ ALK6, IC50: 16.7 nM					99%+
LDN-212854	++++ ALK1, IC50: 2.4 nM	++++ ALK2, IC50: 1.3 nM	+ ALK3, IC50: 85.8 nM	+ ALK4, IC50: 2133 nM				+ ALK5, IC50: 9276 nM		99%+
ML347	++ ALK1, IC50: 46 nM	++ ALK2, IC50: 32 nM								98%
K02288	++++ ALK1, IC50: 1.8 nM	++++ ALK2, IC50: 1.1 nM	++ ALK3, IC50: 34.4 nM		+++ ALK6, IC50: 6.4 nM					99%+
LDN-193189 2HCl	++++ ALK1, IC50: 0.8 nM	++++ ALK2, IC50: 0.8 nM	+++ ALK3, IC50: 5.3 nM		+++ ALK6, IC50: 16.7 nM					99%
LDN-214117		++ ALK2, IC50: 24 nM								98%
DMH-1		+ ALK2, IC50: 107.9 nM								99%+
SB-505124				+ ALK4, IC50: 129 nM				++ ALK5, IC50: 47 nM		99%+
Vactosertib				+++ ALK4, IC50: 13 nM				+++ ALK5, IC50: 11 nM		99%+
Alantolactone						✔				98%
(E/Z)-SIS3 free base						✔				97%
Pirfenidone							✔			98%
Hesperetin							✔			97%
RepSox								++++ TGFβR1(ALK5), IC50: 4 nM		98%
GW788388								+++ ALK5, IC50: 18 nM		98%
LY364947								++ TGFβRI, IC50: 59 nM	+ TGFβRII, IC50: 0.4 μM	98%
SD-208								++ TGF-βRI (ALK5), IC50: 48 nM		99%
SB-525334								+++ TGFβR1(ALK5), IC50: 14.3 nM		99%+
LY2109761								++ TβRI, Ki: 38 nM	+ TβRII, Ki: 300 nM	99%+
Galunisertib								++ TβRI, IC50: 56 nM		98%
SB 431542								+ ALK5, IC50: 94 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Decursin/紫花前胡素生物活性

描述

Decursin, identified as (+)-Decursin, serves as a potent anti-tumor agent with additional cytotoxic properties and the ability to activate protein kinase C significantly. It triggers apoptosis and causes cell cycle arrest in the G1 phase while reducing the expression of CDK2, CDK4, CDK6, and cyclin D1 proteins over 48 hours. Beyond its anti-tumor capacity, Decursin also displays anti-inflammatory and analgesic effects, inhibiting cell proliferation and migration^[1].^[2].^[3].^[4].

体内研究

In in vivo models, Decursin demonstrates anti-tumor activity at a dosage of 4 mg/kg, administered subcutaneously daily for four weeks in mice^[2].

Additionally, at a dosage of 50 mg/kg via intrathecal injection three times at two-day intervals over six days, it exhibits analgesic properties in a mouse model of paclitaxel-induced peripheral neuropathy^[3].

体外研究

In DU145 cells, Decursin exhibits a dose- and time-dependent inhibition of cell growth when administered in concentrations of 0, 25, 50, and 100 μM over periods of 24, 48, 72, and 96 hours^[1].

Decursin not only induces apoptosis and G1 phase cell cycle arrest in DU145 cells but also leads to G1, S, and G2-M phase arrests in PC-3 cells^[1].

Additionally, at concentrations of 0, 25, 50, and 100 μM over 24 and 48 hours, Decursin significantly decreases the levels of CDK2, CDK4, CDK6, and cyclin D1 protein in DU145 cells^[1].

Further studies reveal that Decursin, at concentrations of 0, 5, 20, and 100 μM over seven days, inhibits both the proliferation and differentiation abilities of AC133+ cells^[2]. It also dose-dependently blocks SDF-1α-induced activation of Akt, ERK1/2, and eNOS^[2].

Decursin/紫花前胡素细胞实验

Cell Line BEAS-2B Calu-1 H1299 H596 A549 HT22 cells HT22 cells HT22 cells HT22 cells F11 cells F11 cells HCT-8 colorectal cancer cells HCT-116 colorectal cancer cells Peripheral blood lymphocytes (PBL) U937 cells HL-60 cells KBM-5 cells	Concentration	Treated Time	Description	References
BEAS-2B	60 μM	1 h	To evaluate the effect of Decursin on ROS generation in normal cells, results showed that Decursin did not significantly induce ROS generation in normal cells	Br J Pharmacol. 2016 Mar;173(6):1033-44
Calu-1	150 μM	24 h	To evaluate the effect of Decursin on cell viability, results showed that Decursin significantly reduced the viability of NSCLC cells	Br J Pharmacol. 2016 Mar;173(6):1033-44
H1299	150 μM	24 h	To evaluate the effect of Decursin on cell viability, results showed that Decursin significantly reduced the viability of NSCLC cells	Br J Pharmacol. 2016 Mar;173(6):1033-44
H596	150 μM	24 h	To evaluate the effect of Decursin on cell viability, results showed that Decursin significantly reduced the viability of NSCLC cells	Br J Pharmacol. 2016 Mar;173(6):1033-44
A549	150 μM	24 h	To evaluate the effect of Decursin on cell viability, results showed that Decursin significantly reduced the viability of NSCLC cells	Br J Pharmacol. 2016 Mar;173(6):1033-44
HT22 cells	25 and 50 µM	6 h	Evaluate the effect of Decursin on HO-1 expression in HT22 cells, results showed Decursin significantly increased HO-1 expression levels.	Antioxidants (Basel). 2023 Aug 21;12(8):1651
HT22 cells	25 and 50 µM	8 h	Evaluate the effect of Decursin on glutamate-induced ROS accumulation in HT22 cells, results showed Decursin significantly reduced ROS accumulation.	Antioxidants (Basel). 2023 Aug 21;12(8):1651
HT22 cells	25 µM	12 h	Evaluate the protective effect of Decursin on glutamate-induced chromatin condensation in HT22 cells, results showed Decursin significantly reduced chromatin condensation.	Antioxidants (Basel). 2023 Aug 21;12(8):1651
HT22 cells	12.5 and 25 µM	24 h	Evaluate the protective effect of Decursin on glutamate-induced HT22 cell death, results showed Decursin significantly improved cell viability.	Antioxidants (Basel). 2023 Aug 21;12(8):1651
F11 cells	2 μM	12 h	Decursin significantly increased the number and length of neurites in F11 cells, promoting neuronal regeneration.	Cells. 2021 Mar 4;10(3):547
F11 cells	0.5 and 1 μM	30 seconds	Decursin significantly inhibited the rapid elevation of intracellular Ca2+ levels induced by capsaicin in a concentration-dependent manner.	Cells. 2021 Mar 4;10(3):547
HCT-8 colorectal cancer cells	3.125, 6.25, 12.5, 25, 50, 100, 200 µM	24, 48, 72 h	To evaluate the effect of Decursin on the growth of HCT-8 cells, results showed that Decursin inhibited cell viability in a dose- and time-dependent manner.	Int J Mol Sci. 2024 Sep 14;25(18):9939
HCT-116 colorectal cancer cells	3.125, 6.25, 12.5, 25, 50, 100, 200 µM	24, 48, 72 h	To evaluate the effect of Decursin on the growth of HCT-116 cells, results showed that Decursin inhibited cell viability in a dose- and time-dependent manner.	Int J Mol Sci. 2024 Sep 14;25(18):9939
Peripheral blood lymphocytes (PBL)	80 μM	24 h	To evaluate the cytotoxic effect of Decursin on PBL, results showed no cytotoxicity at concentrations up to 80 μM.	Cancer Lett. 2010 Dec 8;298(2):212-21
U937 cells	20, 80 μM	24 h	To evaluate the cytotoxic effect of Decursin on U937 cells, results showed cytotoxicity starting at 20 μM, becoming prominent at 80 μM.	Cancer Lett. 2010 Dec 8;298(2):212-21
HL-60 cells	80 μM	24 h	To evaluate the cytotoxic effect of Decursin on HL-60 cells, results showed an apoptotic effect at 80 μM.	Cancer Lett. 2010 Dec 8;298(2):212-21
KBM-5 cells	10, 20, 40, 80 μM	24 h	To evaluate the cytotoxic effect of Decursin on KBM-5 cells, results showed that Decursin started to be cytotoxic at 10 μM and exhibited dose-dependent cytotoxicity.	Cancer Lett. 2010 Dec 8;298(2):212-21

Cell Line

Concentration

Treated Time

Description

References

BEAS-2B

60 μM

1 h

To evaluate the effect of Decursin on ROS generation in normal cells, results showed that Decursin did not significantly induce ROS generation in normal cells